Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065505 | 0.79 | FFAR1 (0.53) | ALDH1A1KDM4CCYP1A2CYP2C19FAAH | |
| SCHEMBL10301465 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 | |
| SCHEMBL1545706 | 0.76 | FAAH (0.41) | FAAHTSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL6228969 | 0.73 | MAPT (0.49) | ALDH1A1HPGDMAPK1CYP1A2CYP2C9 | |
| SCHEMBL28926384 | 0.72 | HPGD (0.49) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 | |
| SCHEMBL15078047 | 0.72 | ALDH1A1 (0.72) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 | |
| SCHEMBL28926378 | 0.72 | HPGD (0.49) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 | |
| SCHEMBL28926382 | 0.72 | HPGD (0.49) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 | |
| SCHEMBL16187787 | 0.71 | ALDH1A1 (0.78) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 | |
| SCHEMBL4389396 | 0.71 | ALDH1A1 (0.78) | ALDH1A1KDM4CHPGDMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1928827-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | APP, PSEN2, PSEN1 | ALDH1A1 4389/4885KDM4C 4758/4885HPGD 963/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | ALDH1A1 4389/4885KDM4C 4758/4885HPGD 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.